South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast becoming the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results